Health authorities have decided against expanding routine prostate cancer testing for men, citing concerns over unnecessary treatments. The UK National Screening Committee emphasized that widespread testing could lead to unnecessary surgeries and over-treatment, especially for Black men and those with a family history of the disease.

Despite calls from prominent figures like Sir Chris Hoy for increased screening, the committee determined that current blood tests are not sufficiently accurate and could result in unnecessary interventions for benign conditions that pose no real threat.

While acknowledging the benefits of prostate cancer screening in reducing cancer-related deaths to some extent, the committee highlighted that overall survival rates are not significantly improved. They stressed the importance of distinguishing between harmful and harmless forms of the disease to avoid unnecessary treatments.

Prostate cancer has become increasingly prevalent in the UK, partly due to heightened awareness leading to more men seeking testing. Men experiencing symptoms can request a blood test from their GP.

Advocates, including Sir Chris Hoy, have pushed for targeted screening for men with known risk factors, such as a family history of the disease, even in the absence of symptoms. However, concerns persist over the reliability of the PSA test commonly used for screening.

The committee cautioned that while screening may reduce some prostate cancer deaths, the risk of overdiagnosis and overtreatment remains significant. Overtreatment, often involving surgical removal of the prostate, can have lasting negative impacts on quality of life.

Experts emphasized the challenges in determining the necessity of treatment for prostate cancer and highlighted the psychological burden on men diagnosed with the disease. The committee’s revised recommendation focuses on targeted screening for men with specific genetic risks.

While the decision has faced criticism from some organizations advocating for broader screening programs, the government is likely to follow the committee’s guidance. Cancer research experts stress the importance of evidence-based decisions to avoid unnecessary harm from invasive treatments.

Prostate Cancer UK expressed disappointment with the outcome, noting the potential benefits of a mass screening program. However, the organization acknowledged the need for further evidence to support broader screening initiatives.

The Department of Health and Social Care assured that the recommendation would be carefully considered before any government response is finalized.